Azafaros

Azafaros is a biopharmaceutical company dedicated to developing innovative therapies for severe rare metabolic disorders, particularly neurogenetic diseases. The company operates in the rare disease market, targeting conditions that have limited treatment options. Azafaros' business model revolves around drug discovery and development, with a focus on advancing its clinical candidate, AZ 3102, an orally available azasugar designed to treat the central nervous system and interfere with the metabolism of glycosphingolipids. This candidate is currently in the clinical stage and aims to modify disease pathways through a unique dual mode of action. The company generates revenue through partnerships, investments, and potential future sales of its therapeutic products. Azafaros is backed by a syndicate of leading Dutch and Swiss investors, including Forbion, BioGeneration Ventures, BioMedPartners, and Schroder Adveq. The company leverages the expertise of its team and partners in orphan drug development to expand its product pipeline and bring new treatment options to patients with rare metabolic diseases.

Keywords: biopharmaceutical, rare diseases, neurogenetic, azasugar, glycosphingolipids, clinical stage, drug discovery, orphan drug, investors, therapeutic products.